Literature DB >> 17521325

Susceptibility genes in Graves' ophthalmopathy: searching for a needle in a haystack?

Tomasz Bednarczuk1, Bamini Gopinath, Rafal Ploski, Jack R Wall.   

Abstract

The variety of clinical presentations of eye changes in patients with Graves' disease suggests that complex interactions between genetic, environmental, endogenous and local factors influence the development/severity of Graves' ophthalmopathy (GO). At present, the role of genetic factors in the development of GO remains unknown. Based on small case-control association studies with candidate genes, several susceptibility loci in GO have been proposed. These are human leucocyte antigen (HLA, 6p21.3), cytotoxic T-lymphocyte antigen-4 (CTLA-4, 2q33), tumour necrosis factor (TNF, 6p21.3), interferon-gamma (IFN-gamma, 12q14), intercellular adhesion molecule-1 (ICAM-1, 19p13), and thyroid stimulating hormone receptor gene (TSH-R, 14q31). Unfortunately, these results were either not confirmed or require replication in larger studies. There are many reasons for the lack of reproducibility of association studies in GO, including poor characterization of the studied groups and small sample sizes, which may result in both false positive and negative results. Thus, the genetic background of GO remains to be elucidated in future research. However, the possibility that GO may be a genetically heterogeneous disorder, or that the development of GO may be predominantly influenced by environmental factors such as cigarette smoking, can not be disregarded.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17521325     DOI: 10.1111/j.1365-2265.2007.02854.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  25 in total

Review 1.  Graves orbitopathy: a perspective.

Authors:  Petros Perros; Gerasimos E Krassas
Journal:  Nat Rev Endocrinol       Date:  2009-06       Impact factor: 43.330

2.  Perimysial fibroblasts of extraocular muscle, as unique as the muscle fibers.

Authors:  Linda L Kusner; Andrew Young; Steven Tjoe; Patrick Leahy; Henry J Kaminski
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-08-06       Impact factor: 4.799

Review 3.  Graves' ophthalmopathy.

Authors:  Rebecca S Bahn
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

Review 4.  Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies.

Authors:  David J Byun; Jedd D Wolchok; Lynne M Rosenberg; Monica Girotra
Journal:  Nat Rev Endocrinol       Date:  2017-01-20       Impact factor: 43.330

5.  Association of polymorphisms of rs179247 and rs12101255 in thyroid stimulating hormone receptor intron 1 with an increased risk of Graves' disease: A meta-analysis.

Authors:  Jing Gong; Shu-Jun Jiang; Ding-Kun Wang; Hui Dong; Guang Chen; Ke Fang; Jin-Rui Cui; Fu-Er Lu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-07-28

6.  Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy.

Authors:  Le Min; Anand Vaidya; Carolyn Becker
Journal:  Eur J Endocrinol       Date:  2010-11-18       Impact factor: 6.664

Review 7.  The eye and thyroid disease.

Authors:  Ajay E Kuriyan; Richard P Phipps; Steven E Feldon
Journal:  Curr Opin Ophthalmol       Date:  2008-11       Impact factor: 3.761

8.  Pathogenesis of thyroid-associated ophthalmopathy: does autoimmunity against calsequestrin and collagen XIII play a role?

Authors:  Hooshang Lahooti; Kishan R Parmar; Jack R Wall
Journal:  Clin Ophthalmol       Date:  2010-05-14

9.  Update on the medical treatment of Graves' ophthalmopathy.

Authors:  Gregory J Griepentrog; James A Garrity
Journal:  Int J Gen Med       Date:  2009-12-29

10.  Update on thyroid eye disease and management.

Authors:  Erick D Bothun; Ryan A Scheurer; Andrew R Harrison; Michael S Lee
Journal:  Clin Ophthalmol       Date:  2009-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.